A carregar...
Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
Enzalutamide, a second-generation small-molecule inhibitor of the androgen receptor (AR), has been approved for patients who failed with androgen deprivation therapy and have developed castration-resistant prostate cancer. More than 80% of these patients develop bone metastases. The binding of enzal...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5992404/ https://ncbi.nlm.nih.gov/pubmed/29911070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00180 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|